SAN DIEGO, March 15, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two abstracts have been accepted for poster presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago at McCormick Place North/South.
Details for Biocept's poster presentations are as follows:
Title: Target SelectorTM CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (link to abstract)
Session Category/Title: Clinical Research/Liquid Biopsy
Session Date and Time: Wednesday Apr 18, 2018, 8:00 a.m.-12:00 p.m. CDT
Location: McCormick Place South, Exhibit Hall A, Poster Section 26
Title: Validation of highly sensitive Target SelectorTM ctDNA assays for EGFR, BRAF, and KRAS mutations (link to abstract)
Session Category/Title: Clinical Research/Diagnostic Biomarkers
Session Date and Time: Tuesday Apr 17, 2018, 1:00 p.m.-5:00 p.m. CDT
Location: McCormick Place South, Exhibit Hall A, Poster Section 24, Poster Board #19
"Capturing and analyzing circulating tumor cells (CTCs) with Biocept's liquid biopsy technology has demonstrated the ability to correlate CTCs with clinical responses in refractory testicular cancer," said Shilpa Gupta, MD, Assistant Professor in the Division of Hematology, Oncology and Transplantation at Masonic Cancer Center, University of Minnesota. "Refractory testicular cancers have extremely poor prognosis and novel treatments are urgently needed to improve outcomes. In our ongoing phase 2 study of brentuximab vedontin, an anti-CD-30 antibody with bevacizumab in refractory CD-30 + germ cell tumors, we are utilizing CTCs with Biocept's liquid biopsy technology both at baseline and serially to assess correlation with clinical response. The ability of this technology to detect molecular markers of interest holds promise for improving the assessment of patients with this disease and offers a precision medicine based approach to treating these cancers."
"Our collaboration with the Masonic Cancer Center at University of Minnesota and the Huntsman Cancer Center demonstrates proof-of-concept for the use of our Target Selector™ CTC platform to monitor advanced testicular cancer," said Biocept's Senior Vice President and Senior Medical Director Veena Singh, MD. "This not only exhibits utility in a new tumor type for Biocept, but also shows the versatility of our antibody cocktail for the capture and analysis of circulating tumor cells associated with multiple cancer types. We look forward to advancing our ongoing work with our collaborators to further demonstrate the clinical utility of our non-invasive liquid biopsy tests in genitourinary cancer."
"We are pleased to present data at this year's AACR Annual Meeting highlighting the leading performance of our Target Selector™ assays and the ability to identify actionable biomarkers associated with metastatic cancers," said Biocept's President and CEO Michael Nall. "We believe that these results add to the body of evidence supporting the analytical performance and clinical utility of our proprietary molecular diagnostic technologies, and further solidify our leadership position in the emerging liquid biopsy segment."
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, and our ability to advance our ongoing work with our collaborators to further demonstrate the clinical utility of our non-invasive liquid biopsy tests, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
SOURCE Biocept, Inc.